New UK Market Surveillance Levy Could Cost Medtech Companies Millions Each Year
This article was originally published in The Gray Sheet
Executive Summary
The exact size of the fee is not yet known, but the UK's Medicines and Healthcare products Regulatory Agency apparently says it will be necessary to maintain fully functioning market oversight.
You may also be interested in...
NICE Cost-Recovery-Plan Pause Is Welcome News For UK Industry
The UK National Institute for Health and Care Excellence will wait for the government to finalize its life sciences strategy before deciding on whether to go ahead with its plan to levy a fee for technology appraisals. Pharmaceutical and medtech companies say the delay by NICE will allow more time for their concerns over the proposal to be explored.
NICE Cost Recovery Plans Pause Is Welcome News For UK Industry
UK health technology body NICE will wait for the government to finalize its life sciences strategy before deciding on whether to go ahead with its plan to levy a fee for technology appraisals. Pharmaceutical and medtech companies say the delay will allow more time for their concerns over the proposal to be explored.
Europe Readies For Big Changes In Device Postmarket Surveillance
Europe may be on the cusp of a big drive toward a more clearly organized and more transparent postmarket vigilance system with new funds directed at the issue in the wake of device safety scandals. The European Commission recently launched the second phase of its joint action plan of near-term device and diagnostics reforms, pushing postmarket surveillance to the top of its agenda.